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We agree with Lee 1 that observational studies are limited by unmeasured and unknown 
confounding which can be best handled by a sufficiently powered randomised controlled trial.  
As mentioned in the discussion of our paper, we also acknowledge that Chou et al in their 
research on the Taiwanese National Health Insurance Research Database found that csDMARD 
increases the risk of Alzheimer's disease rather than providing protection.2 It is interesting that 
both studies failed to epidemiologically capture any positive anti-inflammatory effects or 
suppression of microglial neurotoxicity induced by β-amyloid protein hypothesised to be 
triggered by these drugs. Further, as described in our paper,3 the effect of hydroxychloroquine 
on progression of dementia in early Alzheimer's disease has already been investigated in an 18-
month randomized, placebo-controlled trial that included 168 patients with early Alzheimer’s 
disease which showed no effect of the treatment against placebo.4 There are no randomised 
controlled trials to date that evaluate effects of these drugs on primary prevention of 
Alzheimer’s disease.  This is because such trials would have to run for several years and would 
need to recruit very large numbers of people in order to provide a meaningful result.  In the 
absence of such evidence large observational studies offer the best next level of evidence on 
which we as clinicians can judge the effectiveness and/or safety of drugs. 
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